Literature DB >> 2301701

Reexcision perineural invasion. Not a sign of malignancy.

J B Stern1, H M Haupt.   

Abstract

Perineural invasion has been reported to occur in both benign and malignant neoplasms. We describe two cases in which perineural invasion by epithelial cells was present in reexcision skin specimens removed because of melanocytic lesions in the original biopsy material. Because of the absence of a primary epithelial neoplasm, this phenomenon was interpreted as a reactive or reparative process, most probably resulting from regenerating traumatized sweat gland ducts. On the basis of this study alone, it may not be possible to distinguish between reexcision perineural invasion and perineural invasion from a primary epithelial neoplasm. For such cases, the following histologic features serve as provisional guidelines favoring an interpretation of reexcision perineural invasion: absence of perineural spread beyond the immediate previous biopsy site, benign appearance of the perineural epithelial cells different from the appearance of the original tumor, and absence of residual epithelial tumor in the vicinity of the involved perineurium.

Entities:  

Mesh:

Year:  1990        PMID: 2301701     DOI: 10.1097/00000478-199002000-00010

Source DB:  PubMed          Journal:  Am J Surg Pathol        ISSN: 0147-5185            Impact factor:   6.394


  3 in total

Review 1.  [Squamous epithelial carcinomas of the face with neurotropic growth].

Authors:  S Ständer; H Ständer; H Kutzner; T A Luger; D Metze
Journal:  Hautarzt       Date:  2003-06-25       Impact factor: 0.751

2.  Perineural Invasion in the Absence of Malignancy: Report of Two Cases and Review of the Literature.

Authors:  Katrin Pfaltz; André Barghorn; Werner Kempf
Journal:  Dermatopathology (Basel)       Date:  2014-11-08

3.  Epithelial sheath neuroma: A case series.

Authors:  Akshay Flora; Roger H Kim; Alexis D Lara Rivero; Urszula Carr; Frank Isaacs
Journal:  JAAD Case Rep       Date:  2020-02-26
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.